<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> effects of <z:chebi fb="0" ids="10127">zonisamide</z:chebi> (ZNS) have been well documented experimentally and clinically </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study was to examine whether ZNS reduces cerebral damage after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> was induced by a transient occlusion of the left middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) with a 3-0 nylon monofilament for 90 min </plain></SENT>
<SENT sid="3" pm="."><plain>Neurological evaluation was performed by measuring the event of neurological deficit of the contralateral forepaw and hindpaw at 10 min and 1 day after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion (MCAo) </plain></SENT>
<SENT sid="4" pm="."><plain>Brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size was determined by measuring triphenyltetrazonium <z:chebi fb="76" ids="17996">chloride</z:chebi>-negative stained area of the serial brain sections 1 day after MCAo </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The pre- or postischemic treatment with ZNS [(10-100 mg/kg p.o.), 30 min before and 4 h after or 15 min and 4 h after the occlusion] markedly reduced cerebral damage in the ipsilateral hemisphere and the neurological deficit induced by <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The reducing effect on the damage was observed in the cortical and subcortical regions </plain></SENT>
<SENT sid="7" pm="."><plain>Preischemic treatment with carbamazepine (CBZ 60 mg/kg p.o. twice 30 min before and 4 h after MCAo) tended to reduce the cerebral damage and neurological deficit, but the lower dose (20 mg/kg p.o </plain></SENT>
<SENT sid="8" pm="."><plain>twice) did not </plain></SENT>
<SENT sid="9" pm="."><plain>Valproate (VPA 1,000 mg/kg p.o </plain></SENT>
<SENT sid="10" pm="."><plain>twice) also had no effect </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: ZNS at the <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> dose, unlike CBZ and VPA, ameliorated the <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and the event of neurological deficit after transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>These data suggest that ZNS has therapeutic potential in protecting against ischemic cerebral damage, such as <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>